Oral mucositis (severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
2 findings from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in survival rates at 3 years compared with best supportive care (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
Epidermal growth factor may leads to higher survival rates at 5 years compared with best supportive care (low certainty).
1 finding from 1 review
Health‐related quality of life · People with advanced non‐small cell lung cancer
It is very uncertain whether epidermal growth factor changes health‐related quality of life compared with best supportive care (very low certainty).
1 finding from 1 review
Overall survival · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in overall survival compared with best supportive care (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
Epidermal growth factor showed no clear difference in participants with at least one serious adverse event compared with best supportive care (low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Epidermal growth factor led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Erlotinib showed no clear difference in overall survival compared with control (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Erlotinib leads to lower progression‐free survival compared with control (high certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Overall survival · EGFR M+ patients with NSCLC
Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).
1 finding from 1 review